基于BAFF与IFN-I生物活性对SLE进行分层以指导生物制剂选择及肾小球来源BAFF在狼疮肾炎中的意义
研究建立BAFF报告细胞检测SLE患者血清和尿液BAFF生物活性,并结合IFN-I生物活性进行分层。结果显示狼疮肾炎(LN)患者血清BAFF生物活性显著高于健康对照和非LN患者,尿液BAFF生物活性在LN患者中升高,肾小球巨噬细胞和系膜细胞表达BAFF;高BAFF对应LN,高IFN-I对应血液和皮肤表现。作者认为监测尿液BAFF生物活性可能有助于诊断LN,基于血清BAFF和IFN-I生物活性的分层可能有助于识别适合靶向BAFF和IFN-I生物制剂的患者。
要点
- LN患者血清BAFF生物活性显著高于健康对照和非LN患者。
- LN患者尿液BAFF生物活性升高,尿液未检测到IFN-I生物活性。
- LN患者肾小球巨噬细胞和系膜细胞表达BAFF。
核心结论
- 监测尿液BAFF生物活性可能对诊断LN有价值。
- 基于血清BAFF和IFN-I生物活性的分层可能有助于识别适合靶向BAFF和IFN-I生物制剂的患者。
研究设计与样本
- 研究建立BAFF报告细胞,检测SLE患者血清BAFF生物活性并分析高BAFF生物活性患者的临床特征。
- 利用公开单细胞RNA测序数据和免疫组织学分析鉴定肾脏中表达BAFF的细胞。
- 根据BAFF和I型干扰素(IFN-I)生物活性对SLE患者进行分层,以识别相关临床特征。
主要发现
- SLE患者尤其LN患者血清BAFF生物活性显著高于健康对照和非LN患者。
- LN患者肾脏单细胞RNA测序数据和免疫组织学分析显示BAFF表达于肾小球巨噬细胞和系膜细胞。
- LN患者尿液BAFF生物活性较非LN患者升高,而尿液中未检测到IFN-I生物活性。
- 基于血清BAFF和IFN-I生物活性的SLE分层显示:高BAFF代表LN患者,高IFN-I代表有血液和皮肤表现的患者。
关键数值与推荐
- LN患者血清BAFF生物活性显著高于健康对照和非LN患者。
- LN患者尿液BAFF生物活性较非LN患者升高,尿液中未检测到IFN-I生物活性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: B-cell activating factor (BAFF) is implicated in SLE pathogenesis. Blocking BAFF signalling has contributed to reducing glucocorticoid dosage and preventing organ damage. However, clinical characteristics of patients who may benefit from this therapy are not yet fully elucidated. Therefore, we identified patients with high BAFF-bioactivity to investigate their clinical characteristics and BAFF-producing cells. METHODS: We established the reporter cell for BAFF and investigated the clinical characteristics of SLE patients with high BAFF-bioactivity. We identified BAFF-expressing kidney cells using publicly available scRNA-seq data and immunohistological analysis. SLE patients were stratified based on the bioactivity of BAFF and type-I IFN (IFN-I) to identify associated characteristic clinical manifestations. RESULTS: SLE patients, especially patients with LN, had significantly higher serum BAFF-bioactivity than healthy controls (HC) and non-LN patients. Additionally, single-cell-RNA-seq data and immunohistological analysis of kidney samples from LN patients revealed that BAFF is expressed in glomerular macrophages and mesangial cells. Notably, BAFF bioactivity was elevated in the urine of LN patients compared with that of non-LN patients, while no IFN-I bioactivity was detected in the urine. Furthermore, SLE stratification based on bioactivities of serum BAFF and IFN-I revealed the clinical characteristics of patients: high BAFF represented patients with LN and high IFN-I represented patients with blood and skin manifestations. CONCLUSIONS: Monitoring urinary BAFF-bioactivity may be valuable in diagnosing LN. Furthermore, stratification based on serum BAFF and IFN-I bioactivities may allow the identification of appropriate patients for biologics targeting BAFF and IFN-I.
引用
- Itotagawa E, Tomofuji Y, Kato Y, et al. SLE stratification based on BAFF and IFN-I bioactivity for biologics and implications of BAFF produced by glomeruli in lupus nephritis. Rheumatology (Oxford). 2023. PMID: 36094336. doi:10.1093/rheumatology/keac528
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。